Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.

NCT04479553 is registered in ClinicalTrials.gov with Zhong Wang as lead sponsor.

NCT NCT04479553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04479553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.
Lead sponsor
Zhong Wang
Phase
Observational
Overall status
Unknown status
Start date
August 17, 2020
Completion date
December 31, 2023
Enrollment
30,000 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

adverse drug events, adverse drug reactions, safety surveillance, severe adverse events, severe adverse reactions